Cargando…

Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program

OBJECTIVES: To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX. METHODS: Radiographic progression was assessed in two phase 3 randomized controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterfy, Charles G, Strand, Vibeke, Friedman, Alan, Hall, Stephen, Mysler, Eduardo, Durez, Patrick, Baraliakos, Xenofon, Enejosa, Jeffrey V, Shaw, Tim, Li, Yihan, Chen, Su, Song, In-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348768/ https://www.ncbi.nlm.nih.gov/pubmed/34897366 http://dx.doi.org/10.1093/rheumatology/keab861

Ejemplares similares

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
por: Fleischmann, Roy M, et al.
Publicado: (2019)

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
por: Fleischmann, Roy, et al.
Publicado: (2022)

Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE
por: Strand, Vibeke, et al.
Publicado: (2021)

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
por: Conaghan, Philip G., et al.
Publicado: (2021)

Upadacitinib for rheumatoid arthritis
Publicado: (2020)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
por: Kivitz, Alan, et al.
Publicado: (2023)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
por: Strand, Vibeke, et al.
Publicado: (2020)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
por: Burmester, Gerd R, et al.
Publicado: (2023)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Charles-Schoeman, Christina, et al.
Publicado: (2023)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
por: Mysler, Eduardo, et al.
Publicado: (2022)

Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
por: Zeng, Xiaofeng, et al.
Publicado: (2021)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2019)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
por: Strand, Vibeke, et al.
Publicado: (2020)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
por: Cohen, Stanley B, et al.
Publicado: (2021)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan
por: Yamaoka, Kunihiro, et al.
Publicado: (2021)

Lymphomatoid papulosis during upadacitinib treatment for rheumatoid arthritis
por: Iinuma, Shin, et al.
Publicado: (2022)

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
por: Sanmartí, Raimon, et al.
Publicado: (2023)

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
por: Winthrop, Kevin L, et al.
Publicado: (2022)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis
por: Fournier, Cynthia, et al.
Publicado: (2023)

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial
por: van Vollenhoven, Ronald, et al.
Publicado: (2020)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis
por: Bird, Paul, et al.
Publicado: (2018)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials
por: Bergman, Martin, et al.
Publicado: (2022)

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review
por: Emery, Paul, et al.
Publicado: (2021)

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Upadacitinib for the treatment of psoriatic arthritis
por: Fonseca, Diogo, et al.
Publicado: (2023)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis
por: Mortezavi, Mahta, et al.
Publicado: (2023)

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
por: Tak, Paul P, et al.
Publicado: (2011)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
por: Harrington, Robert, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_44rrpnqfc1hk6fbk3ue27lgud9